Voluntary wheel running reduced the effects of acute ethanol on activity and avoidance in C57BL/6J mice

S. Mollenauer,Rebecca Bryson,Carl E. Speck,John R. Chamberlin

DOI: https://doi.org/10.1016/0091-3057(91)90173-Y

1991-07-01

Abstract:

What problem does this paper attempt to address?

Hypertension Management in Older and Frail Older Patients

Athanase Benetos,Mirko Petrovic,Timo Strandberg

DOI: https://doi.org/10.1161/CIRCRESAHA.118.313236

IF: 23.213

2019-10-07

Circulation Research

Abstract:The prevalence of arterial hypertension, particularly systolic hypertension, is constantly rising worldwide. This is mainly the clinical expression of arterial stiffening as a result of the population's aging. Chronic elevation in blood pressure represents a major risk factor not only for cardiovascular morbidity and mortality but also for cognitive decline and loss of autonomy later in life. Clinical evidence obtained in community-dwelling older people with few comorbidities and preserved autonomy supports the beneficial effects of lowering blood pressure in older hypertensive subjects even after the age of 80 years. However, observational studies in frail older individuals treated for hypertension have shown higher morbidity and mortality rates compared with those with lower blood pressure levels. Clearly, in very old subjects, the therapeutic strategy of one size fits all cannot be applied because of the enormous functional heterogeneity in these individuals. Geriatric medicine proposes taking into account the function/frailty/autonomy status of older people. In the present review, we propose to adapt the antihypertensive treatment using an easy-to-apply visual numeric scale allowing the identification of 3 different patient profiles according to the functional status and autonomy for activities of daily living. For the preserved function profile, strategies should be those proposed for younger old adults. For the loss of function/preserved activities of daily living' profile, a more detailed geriatric assessment is needed to define the benefit/risk balance as well as requirements for the tailoring of the various therapeutic strategies. Lastly, for the loss of function and altered activities of daily living' profile, therapeutic strategies should be thoroughly reassessed, including deprescribing (when considered appropriate). In the near future, controlled trials are necessary for the most frail older subjects (ie, in those systematically excluded from previous clinical trials) to gain stronger evidence regarding the benefits of the various therapeutic strategies.

cardiac & cardiovascular systems,peripheral vascular disease,hematology
In vitro studies on granulomatous hypersensitivity to beryllium.

Jon Hanifin,William L. Epstein,Martin J. Cline

DOI: https://doi.org/10.1111/1523-1747.EP12260036

IF: 7.59

1970-10-01

Journal of Investigative Dermatology

Abstract:Lymphocytes were obtained from normal subjects and subjects with granulomatous hypersensitivity to beryllium. Lymphocytes from sensitive persons underwent typical blastogenic transformation when exposed to BeO or BeSO 4 in vitro . Transformation was maximal between the fifth and sixth days of exposure and was dependent upon the concentration of beryllium. Monocytes from beryllium sensitive subjects matured into macrophages in vitro more rapidly than cells from normal subjects. Macrophages from sensitive persons, after phagocytizing particulate BeO, were capable of inducing blastogenic transformation of autologous lymphocytes.
Frailty and hypertension in older adults: current understanding and future perspectives

Pan Liu,Yun Li,Yaxin Zhang,Seyed Erfan Mesbah,Tong Ji,Lina Ma

DOI: https://doi.org/10.1038/s41440-020-0510-5

Abstract:Hypertension is an important factor affecting the health of older adults. Antihypertensives can reduce stroke, cardiovascular events, and mortality in older hypertensive patients. Blood pressure management is difficult in older adults since geriatric syndromes such as frailty and comorbidities often coexist with hypertension. Recent guidelines propose taking functional status into account when targeting blood pressure in older people. Therefore, a better understanding and control of frailty risk factors could improve the prognosis of older adults with hypertension. However, there are relatively few studies on hypertension and frailty in older adults, especially studies focused on antihypertensive treatment. The goals, target values, and choice of antihypertensive treatment for frail older adults are still disputed. We reviewed the recent literature focusing on frailty and hypertension in older adults and propose a management process for screening and assessing frailty and hypertension before the use of antihypertensives. The process can support older adults with lifestyle interventions and frailty management and help them begin taking a single antihypertensive medication.
Hypertension in frail older adults: current perspectives

Liying Li,Linjia Duan,Ying Xu,Haiyan Ruan,Muxin Zhang,Yi Zheng,Sen He

DOI: https://doi.org/10.7717/peerj.17760

IF: 3.061

2024-07-11

PeerJ

Abstract:Hypertension is one of the most common chronic diseases in older people, and the prevalence is on the rise as the global population ages. Hypertension is closely associated with many adverse health outcomes, including cardiovascular disease, chronic kidney disease and mortality, which poses a substantial threat to global public health. Reasonable blood pressure (BP) management is very important for reducing the occurrence of adverse events. Frailty is an age-related geriatric syndrome, characterized by decreased physiological reserves of multiple organs and systems and increased sensitivity to stressors, which increases the risk of falls, hospitalization, fractures, and mortality in older people. With the aging of the global population and the important impact of frailty on clinical practice, frailty has attracted increasing attention in recent years. In older people, frailty and hypertension often coexist. Frailty has a negative impact on BP management and the prognosis of older hypertensive patients, while hypertension may increase the risk of frailty in older people. However, the causal relationship between frailty and hypertension remains unclear, and there is a paucity of research regarding the efficacious management of hypertension in frail elderly patients. The management of hypertension in frail elderly patients still faces significant challenges. The benefits of treatment, the optimal BP target, and the choice of antihypertensive drugs for older hypertensive patients with frailty remain subjects of ongoing debate. This review provides a brief overview of hypertension in frail older adults, especially for the management of BP in this population, which may help in offering valuable ideas for future research in this field.
Pharmacological management of hypertension in the elderly and frail populations

Ashish Correa,Yogita Rochlani,Mohammed Hassan Khan,Wilbert S. Aronow

DOI: https://doi.org/10.1080/17512433.2018.1500896

2018-07-23

Expert Review of Clinical Pharmacology

Abstract:INTRODUCTION: Cardiovascular disease is a leading cause of mortality in the elderly. Hypertension is an important modifiable risk factor that contributes to cardiovascular morbidity and mortality. The prevalence of hypertension is known to increase with age, and hypertension has been associated with an increase in risk for cardiovascular disease in the elderly. There is a wealth of evidence that supports aggressive control of blood pressure to lower cardiovascular risk in the general population. However, there are limited data to guide management of hypertension in the elderly and frail patient subgroups. These subgroups are inadequately treated due to lack of clarity regarding blood pressure thresholds, treatment targets, comorbidities, frailty, drug interactions from polypharmacy, and high cost of care. Areas covered: We review the current evidence behind the definition, goals, and treatments for hypertension in the elderly and frail and outline a strategy that can be used to guide antihypertensive pharmacotherapy in this population. Expert commentary: Lower blood pressure to < 130/80 mm Hg in elderly patients if tolerated and promote use of combination therapy if the blood pressure is > 20/10 mm Hg over the goal blood pressure. Antihypertensive treatment regimens must be tailored to each individual based on their comorbidities, risk for adverse effects, and potential drug interactions ( Figure 1 ).

pharmacology & pharmacy
Quantification of myocardial late gadolinium enhancement using synthetic inversion recovery imaging

A. Varga-Szemes,R. J. van der Geest,B. Spottiswoode,G. Muscogiuri,C. D. De Cecco,P. Suranyi,W. Rehwald,J. Schoepf

DOI: https://doi.org/10.1186/1532-429X-17-S1-O8

IF: 6.4

2015-02-03

Journal of Cardiovascular Magnetic Resonance

Abstract:
Hypertension Treatment in Frail Older Adults: A Systematic Review and Appraisal of Guidelines

Kaiyan Hu,Gang Zhou,Mengyao Jiang,Xiaohong Wei,Jing Yu,Li Liu,Zhe Wang,Liyuan Feng,Mei Wu,Tao Li,Bin Ma

DOI: https://doi.org/10.1007/s40266-023-01053-1

Abstract:Background: Managing hypertension in frail older patients is challenging. Several institutions and organizations have published up-to-date hypertension guidelines suggesting frailty screening among older hypertensive patients, with new recommendations for blood pressure-lowering treatment among the frail population. However, the quality of current hypertension guidelines and the consistency of antihypertension treatment recommendations for frail older patients and their supporting evidence remain unknown. Objective: In this review, we aimed to systematically collect guidelines with antihypertension treatment recommendations for frail older patients, examine and compare these recommendations, and critically assess reporting and methodology quality of these guidelines. Methods: A literature search was conducted on two databases and three major websites of guideline development organizations. The AGREE instrument and RIGHT checklist were used to evaluate the methodology and reporting quality of the guidelines, respectively. The consistency of recommendations within the guidelines were compared using descriptive analysis. Results: We identified 13 hypertension guidelines. The overall methodology quality scores (range 23.35-79.07%) and reporting rates (range 10/35-29/35) varied among these guidelines. Four guidelines provided an explicit definition of frailty. Considering treatment tolerability or increased likelihood of adverse effects while using pharmacotherapy in frail older patients was mentioned in all guidelines. Ten guidelines recommended adjusting blood pressure targets or specific pharmacotherapy programs. Four guidelines recommended using clinical judgment when prescribing. However, the specific recommendations lacked clarity and unity without sufficient evidence. Conclusions: There were considerable variations in methodology and reporting quality across the 13 included hypertension guidelines. Furthermore, the depth and breadth of antihypertension treatment recommendations for frail older patients were varied and inconsistent. Further trials exploring optimal treatment are urgently required to promote the development of specific guidelines for managing frail older hypertensive patients.
[Study of chromosomes in 35 cases of leukemia].

A. Stahl,M. C. Papy-Jurion,R. Muratore,M. Mongin,J. Olmer

1966-02-19

Abstract:
Current issues in frailty and hypertension management

Koichi Yamamoto

DOI: https://doi.org/10.1038/s41440-023-01310-1

2023-06-06

Hypertension Research

Abstract:The significance of hypertension management in older individuals is greatly influenced by factors other than chronological age, as they have diverse physical, mental, and social backgrounds. Differences in physical functions, between independence, frailty and dependence, have a great impact on antihypertensive therapy in the older population. While recent clinical trials support the significance of intensive antihypertensive therapy regardless of age, there is little evidence to positively support the significance of antihypertensive therapy for older patients with physical function requiring nursing care, and observational studies suggest that antihypertensive treatment may instead be harmful in these older patients. Therefore, frailty, the transitional state between independence and dependence with the need for nursing care, is conceivable to be the tipping point at which the balance of risks and benefits of antihypertensive treatment is converted. The increased risk of acute adverse outcome is another issue that complicates management in the practice of hypertension treatment in frail patients. Particularly, increased blood pressure variability manifested by orthostatic hypotension in frail patients can induce fall and fracture leading to disability shortly after initiation or modification of antihypertensive treatment. Future challenges to optimize the management of frail hypertensive patients include developing techniques to estimate treatment efficacy, identifying safe antihypertensive regimens that reduce the risk of falls, and establishing strategies to restore frail patients to robust health.

peripheral vascular disease
Deprescribing Antihypertensive Drugs in Patients of Older Age Groups

O. D. Ostroumova,M. S. Cherniaeva,D. A. Sychev

DOI: https://doi.org/10.20996/1819-6446-2020-02-14

2020-03-02

Rational Pharmacotherapy in Cardiology

Abstract:Arterial hypertension (AH) is one of the most common diseases in the elderly. It has been proven that lowering blood pressure (BP) is effective in preventing stroke and cardiovascular complications in patients even at the age of ≥80 years. On the other hand, there is evidence that a significant decrease in BP can be harmful to older people and may lead to a higher risk of overall mortality. Therefore, existing guidelines for the treatment of AH determine specific approaches for managing patients of older age groups, where the target BP levels are determined not only by age and concomitant diseases, but also by the presence of frailty. Moreover, there is a need to monitor the dynamics of frailty indicators (social, functional, cognitive and mental status of the patient), since their deterioration may require changes in the tactics of antihypertensive therapy (dose reduction, drug withdrawal or replacement) and changes in target BP levels. In this regard, in recent years, the possibility/necessity of a planned and controlled process of dose reduction, drug withdrawal or replacement, if this drug can be harmful and/or does not bring benefits (deprescribing), has attracted attention. This article is a review of current literature, which presents the design and main characteristics of randomized clinical trials (RCTs) and systematic reviews on the deprescribing of antihypertensive drugs in elderly patients with AH and frailty. An analysis of these studies showed the benefits of deprescribing of antihypertensive drugs for elderly patients with frailty, which avoids potential harm to their health, improves the quality of life and reduces the economic cost of treatment. Therefore, deprescribing of antihypertensive drugs can be used as an additional tool to achieve the necessary target BP values in patients of an older age group. However, for the development of deprescribing of antihypertensive drugs schemes and its introduction into clinical practice, the results of large specially planned RCTs are needed to study this issue.
NESH protein expression switches to the adverse effect of imatinib mesylate

S. Matsuda,Y. Ichigotani,N. Okumura,H. Yoshida,Y. Kajiya,Y. Kitagishi,N. Shirafuji

DOI: https://doi.org/10.1016/j.molonc.2008.03.003

2008-06-01

Molecular Oncology

Abstract:
Management of Hypertension in the Elderly and Frail Patient

Luigina Guasti,Marco Ambrosetti,Marco Ferrari,Franca Marino,Marc Ferrini,Isabella Sudano,Maria Laura Tanda,Iris Parrini,Riccardo Asteggiano,Marco Cosentino

DOI: https://doi.org/10.1007/s40266-022-00966-7

2022-07-30

Abstract:Hypertension is a frequent finding in elderly patients. Hypertension in older age can be both associated with frailty and represent a risk factor for frailty. Hypertension is recognized as a main risk factor for cardiovascular diseases such as heart failure, atrial fibrillation, and stroke and the occurrence of these diseases may provoke a decline in health status and/or worsen the degree of frailty. Blood pressure targets in hypertensive older and frail patients are not completely defined. However, specific evaluations of individual patients and their co-morbidities and assessment of domains and components of frailty, together with weighted consideration of drug use, may help in finding the appropriate therapy.

pharmacology & pharmacy,geriatrics & gerontology,gerontology
Twelve hot questions in the management of hypertension in patients aged 80+ years and their answers with the help of the 2023 European Society of Hypertension Guidelines

Gulistan Bahat,Heloisa Ribeiro,James P Sheppard,Jonathan M K Bogaerts,Miguel Camafort,Dhayana Dallmeier,Tine De Backer,Giovambattista Desideri,Agnieszka Olszanecka,Alexandre Persu,Athanase Protogerou,Marek Rajzer,Agostino Virdis,Andrea Ungar,Thomas Weber,Athanase Benetos,ESH Working Group on Hypertension in older adults

DOI: https://doi.org/10.1097/HJH.0000000000003844

2024-09-05

Abstract:Arterial hypertension is a major risk factor for cardiovascular morbidity and mortality, and highly prevalent in older age, underscoring the importance of its appropriate management. The population is ageing at an increasing rate, with those aged 80+ years being the fastest growing population characterized by high heterogeneity in terms of functionality and autonomy. The prevalence of hypertension rises with increasing age, due to a significant increase in SBP largely as a result of age-related stiffening of the aorta and other large arteries, affecting almost 80% of those aged 80+ years. Appropriate management of blood pressure in this population is a priority for clinicians. Frailty is a condition characterized by marked vulnerability to adverse health outcomes and is common among older adults including those with hypertension. Hypertension increases frailty level and at the same time, individuals with increasing frailty present with more drug-related adverse effects meaning they are less tolerant to blood pressure lowering by medication. Thus, frailty is a factor that should be integrated when treating hypertension in this population. The European Society of Hypertension 2023 Guidelines on the management of Hypertension are the first international guidelines to integrate the concept of adapting blood pressure management in older adults according to their frailty/functionality level, and to propose practical tools for the application of this concept in the daily practice of physicians and other healthcare professionals. The present article prepared by the European Society of Hypertension Working Group on Hypertension in Older Adults aims to further address some important aspects mentioned concisely in the 2023 European Society of Hypertension guidelines, in order to help physicians and other healthcare professionals including those practicing in primary care. To this end, this study discusses 12 'hot questions' which are answered with the help of the 2023 European Society of Hypertension Guidelines. We hope the present article and Working Group's actions will contribute to understanding and applying the ideal management of hypertension in this most vulnerable population.
Isolation and Function of Allophycocyanin B of Porphyridium cruentum.

Arthur C. Ley,Warren L. Butler,Donald A. Bryant,A. N. Glazer

DOI: https://doi.org/10.1104/PP.59.5.974

IF: 7.4

1977-05-01

PLANT PHYSIOLOGY

Abstract:Allophycocyanin B was purified to homogeneity from the eukaryotic red alga Porphyridium cruentum. This biliprotein is distinct from the allophycocyanin of P. cruentum with respect to subunit molecular weights, and spectroscopic and immunological properties. The purified allophycocyanin B has a long wavelength absorption maximum at 669 nm at room temperature and at 675 nm at -196 C while the fluorescence emission maximum is at 673 nm at room temperature and 679 nm at -196 C. The emission spectrum of allophycocyanin shifted only 1 nm, from 659 to 660 nm, on cooling to -196 C, and was the same with allophycocyanin crystals as it was with pure solutions of the pigment. Phycobilisomes from P. cruentum have a major fluorescence emission band at 680 nm at -196 C which emanates from the small amount of allophycocyanin B present in the phycobilisomes. Light energy absorbed by the bulk of the biliprotein pigments is transferred to allophycocyanin B with high efficiency.
Sexual practices among the quiché-speaking mayan population of guatemala.

J. Bertrand,V. Ward,F. Pauc

DOI: https://doi.org/10.2190/FJH0-H8TN-YWF5-4557

International Quarterly of Community Health Education

Abstract:The purpose of this focus group research was to learn more about the sexual behaviors and practices of this population, in part to better understand their resistance to family planning. The Mayan population is made up of some twenty-three linguistically distinct groups, which collectively constitute 37-42 percent of the Guatemalan population. The largest of these groups, the Quiché- speakers, were the focus of the first phase of this research, reported in this article. Years of economic and social subjugation have resulted in a far lower standard of living among the Mayans than the dominant ethnic group in Guatemala, the Ladinos. This difference is reflected in numerous health indicators, including one of the lowest contraceptive prevalence rates in the hemisphere.A total of thirteen groups were conducted among men and women of different age groups. All groups were organized and moderated by a team of five Mayan field workers who spoke the language and were familiar with the culture of the area. While there was initial hesitation to the idea of discussing the highly sensitive topic of sexual behavior in a group setting, the methodology proved appropriate and yielded detailed data on the subject. All sessions were taped, translated to Spanish and transcribed for purposes of analysis.
Managing hypertension in older people: current concepts

James Steckelmacher,Catherine Graham,Carmela Maniero,Ajay Gupta

DOI: https://doi.org/10.1136/dtb.2023.000031

2024-09-25

Abstract:Hypertension management in older people is challenging due to pathophysiological changes brought about by ageing, associated comorbidities, frailty and polypharmacy and often has a poor evidence base. This article gives an overview of these factors and related available evidence with particular attention to clinical issues and consensus guidance.
Hypertension in the Elderly: An Evidence-based Review

A Virdis,R M Bruno,M Fritsch Neves,G Bernini,S Taddei,L Ghiadoni,A. Virdis,R. M. Bruno,M. Fritsch Neves,G. Bernini,S. Taddei,L. Ghiadoni

DOI: https://doi.org/10.2174/138161211798157711

IF: 3.31

2011-09-01

Current Pharmaceutical Design

Abstract:The progressive ageing of world population, and the increasing prevalence hypertension in elderly people are leading to the consideration that hypertension in the elderly is one of the main topic in hypertension treatment. Multiple mechanisms, including stiffening of large arteries, endothelial dysfunction, cardiac remodeling, autonomic dysregulation, renal aspects, contribute to the great prevalence of hypertension in the elderly and to increased cardiovascular morbidity and mortality. Treatment of hypertension can hardly put back older patients in a low risk category, especially if target organ damage is present. Nevertheless, blood pressure control can successfully prevent stroke, cognitive decline, coronary heart disease and heart failure, and reduce mortality in the elderly, and even in patients > 80 years, as recently demonstrated. Blood pressure should be lowered below 140/90 mmHg also in older patients. However the HYVET study suggests that a goal of 150/90 mmHg can be reasonable in patients aged 80 years or more. Drug treatment should be titrated with particular caution to adverse responses and excessive blood pressure lowering.

pharmacology & pharmacy
Pharmacokinetic and pharmacodynamic considerations in the treatment of the elderly patient with hypertension

L.E.J. Peeters,M.P. Kester,L. Feyz,P.M.L.A. Van Den Bemt,B.C.P. Koch,T. Van Gelder,J. Versmissen

DOI: https://doi.org/10.1080/17425255.2019.1588249

2019-03-16

Abstract:INTRODUCTION: Hypertension is an important risk factor for developing cardiovascular diseases. It is more prevalent in the elderly population. Recently updated American and European guidelines recommend treating every elderly patient with hypertension independent of age, starting with a low dose of antihypertensive drugs. However, little information is available on the optimal dosages of antihypertensive drugs to treat the elderly safely. Areas covered: Comorbidities, co-medication and frailty status can alter the clinical outcome of drug treatment and can cause adverse events in the elderly. Also, due to pharmacokinetic and pharmacodynamic changes the interpatient variability when using antihypertensive drugs is considerable. In this review, an overview is given on the extent to which the previously mentioned parameters are changed in elderly patients and what this means for the exposure to antihypertensive medication. Also, recommendations on the starting dose of the most frequently used antihypertensive drugs are given based on literature data. Expert opinion: We believe that recommendations on starting dosages followed by a stepwise increase of dosages will lead to improved blood pressure control and less adverse drug reactions in the elderly patient. This may improve adherence to antihypertensive therapy.

pharmacology & pharmacy,biochemistry & molecular biology,toxicology
Hypertension and Drug Adherence in the Elderly

Michel Burnier,Erietta Polychronopoulou,Gregoire Wuerzner

DOI: https://doi.org/10.3389/fcvm.2020.00049

IF: 3.6

2020-04-07

Frontiers in Cardiovascular Medicine

Abstract:Hypertension is highly prevalent after the age of 65 years affecting more than 60% of individuals in developed countries. Today, there is sufficient evidence from clinical trials that treating elderly subjects with hypertension with antihypertensive medications has a positive benefit/risk ratio even in very elderly patients (>80 years). In recent years, partial or total non-adherence has been recognized as major issues in the long-term management of hypertension in all age categories. However, whether non-adherence is more frequent in hypertensive patients older than 65 years or not is still a matter of debate and the common belief is that adherence is lower in older than in younger patients. Are clinical data supporting this belief? In this brief review, we discuss the topic of drug adherence in elderly in the context of the medical treatment of hypertension. Studies show that drug adherence is actually better in patients aged 65 to 80 years when compared to younger hypertensive patients (<50 years). However, in very old patients (>80 years) the prevalence of non-adherence does increase. In this patients' group, there are specific risk factors for non-adherence such as cognitive ability, depression, and health believes, in addition to classical risk factors for non-adherence. One important aspect in the elderly is the prescription of potentially inappropriate medications that will interfere with the adherence to necessary treatments. In this context, an interesting new concept was developed few years ago, i.e., the process of deprescribing. Thus, today, in addition to conventional guidelines recommendations (use of single pill combinations, individualization of treatments), the evaluation of cognitive abilities, the regular assessment of potentially inappropriate medications, and the process of deprescribing appear to be three new additional steps to improve drug adherence in the elderly and thereby ameliorate the global management of hypertension.

cardiac & cardiovascular systems
Multiagent Based Recommendation System Model for Indexing and Retrieving Learning Objects

Ronaldo Lima Rocha Campos,Rafaela Lunardi Comarella,R. Silveira

DOI: https://doi.org/10.1007/978-3-642-38061-7_31

2013-05-22

Abstract:

Voluntary wheel running reduced the effects of acute ethanol on activity and avoidance in C57BL/6J mice

Hypertension Management in Older and Frail Older Patients

In vitro studies on granulomatous hypersensitivity to beryllium.

Frailty and hypertension in older adults: current understanding and future perspectives

Hypertension in frail older adults: current perspectives

Pharmacological management of hypertension in the elderly and frail populations

Quantification of myocardial late gadolinium enhancement using synthetic inversion recovery imaging

Hypertension Treatment in Frail Older Adults: A Systematic Review and Appraisal of Guidelines

[Study of chromosomes in 35 cases of leukemia].

Current issues in frailty and hypertension management

Deprescribing Antihypertensive Drugs in Patients of Older Age Groups

NESH protein expression switches to the adverse effect of imatinib mesylate

Management of Hypertension in the Elderly and Frail Patient

Twelve hot questions in the management of hypertension in patients aged 80+ years and their answers with the help of the 2023 European Society of Hypertension Guidelines

Isolation and Function of Allophycocyanin B of Porphyridium cruentum.

Sexual practices among the quiché-speaking mayan population of guatemala.

Managing hypertension in older people: current concepts

Hypertension in the Elderly: An Evidence-based Review

Pharmacokinetic and pharmacodynamic considerations in the treatment of the elderly patient with hypertension

Hypertension and Drug Adherence in the Elderly

Multiagent Based Recommendation System Model for Indexing and Retrieving Learning Objects